Call Us: 1.800.873.5297

By

Pradaxa® MDL Update (MDL 2385): $650 Million Settlement Reached in Federal Multidistrict Litigation

PillsThe Plaintiffs’ Steering Committee, appointed by The Honorable Chief Judge David R. Herndon to negotiate the settlement on behalf of all plaintiffs in the Pradaxa® MDL, and Boehringer Ingelheim Pharmaceuticals, Inc. (and affiliates) have negotiated a settlement program in the amount of $650 Million to resolve approximately 4,000 Pradaxa® claims.

Roger C. Denton of Schlichter, Bogard & Denton, LLP serves as Co-Lead Counsel on the Plaintiffs’ Steering Committee in the national Pradaxa® Multidistrict Litigation (MDL 2385) and has been most recently appointed by Chief Judge Herndon to serve as a member of the Pradaxa® Claimants’ Negotiating Committee (PCNC) going forward.  “We are pleased to announce that a settlement has been reached to settle approximately 4,000 Pradaxa® cases,” says Roger Denton. He adds, “The settlement was reached after two years of litigation, which entailed fiercely briefing and arguing countless discovery motions, reviewing millions of pages of documents produced by defendants, and the completion of nearly 50 depositions – both in the United States and in Europe.” Denton further states, “The settlement program announced today is an outstanding result and is in the best interests of our clients who have suffered serious injuries after using Pradaxa®.”

Pradaxa®, which is manufactured by Boehringer Ingelheim Pharmaceuticals, Inc. (and affiliates), is a direct thrombin inhibitor and oral anticoagulant.  Pradaxa was approved in the United States by the Food and Drug Administration (FDA) as a blood thinning medication used to lower the chance of stroke in patients with non-valvular atrial fibrillation.  In 2011, the FDA initiated a formal investigation into serious bleeding events associated with the use of Pradaxa®. Unlike other blood thinning medications, such as Warfarin, there is no known reversal agent or antidote for Pradaxa®. Thousands of individuals filed lawsuits against the manufacturers of Pradaxa® alleging injuries suffered after using Pradaxa®, including serious bleeding events. As a result, in August 2012 the Judicial Panel on Multidistrict Litigation (JPML) consolidated the federal court claims into a Multidistrict Litigation (In re: Pradaxa® (Dabigatran Etexilate) Products Liability Litigation, MDL 2385) before The Honorable Chief Judge David R. Herndon in the United States District Court for the Southern District of Illinois.

About Schlichter, Bogard & Denton, LLP
Schlichter, Bogard & Denton, LLP is a unique law firm that has held numerous leadership positions in other national litigations involving dangerous pharmaceutical medications and unsafe medical devices, including but not limited to: In re: Yasmin® and Yaz® (Drospirenone) Marketing and Sales Practices and Products Liability Litigation (MDL 2100), In re: NuvaRing® Products Liability Litigation (MDL 1964), In re Gadolinium-Based Contrast Products Liability Litigation (MDL 1909), and In re Ortho Evra® Products Liability Litigation (MDL 1742).

The Pharmaceuticals and Medical Litigation Department at Schlichter, Bogard & Denton aggressively represent clients who allege to have suffered injuries as a result of dangerous pharmaceutical medications and unsafe medical devices. The attorneys at Schlichter, Bogard & Denton, LLP who represent such victims include Roger Denton, Kristine Kraft, Beth Wilkins Flieger, Ashley Brittain Landers, and Tara Rocque. With hard work, creative thinking, and strong trial skills, we have earned an outstanding nationwide reputation by representing thousands of individuals who have suffered serious and life-threatening injuries, or even death. If you or a loved has suffered injuries as a result of dangerous pharmaceutical medications or unsafe medical devices, please contact the attorneys at Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297 for your confidential and free consultation.

Schlichter, Bogard & Denton, LLP also welcomes the opportunity to work with other attorneys on these types of cases. Schlichter, Bogard & Denton, LLP is available to either handle these cases or work as co-counsel, so other attorneys are invited to contact an attorney at the firm to explore this opportunity.

The choice of a lawyer is an important decision and should not be based solely on advertisements. The cases discussed do not predict outcomes in future cases. Past results afford no guarantee of future results and every case is different and must be judged on its own merits.

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.